B Nosyk1, J W Bray2, E Wittenberg3, B Aden4, A A Eggman4, R D Weiss5, J Potter6, A Ang7, Y-I Hser7, W Ling7, B R Schackman4. 1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. Electronic address: bnosyk@cfenet.ubc.ca. 2. Department of Economics, University of North Carolina, Greensboro, NC, United States; Research Triangle International, Durham, NC, United States. 3. Harvard School of Public Health, Boston, MA, United States. 4. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, United States. 5. Harvard Medical School, Boston, MA, United States; McLean Hospital, Belmont, MA, United States. 6. Departments of Psychiatry and Anesthesiology (Pain Medicine), Faculty of Medicine, University of Texas Health Science Center, San Antonio, TX, United States. 7. UCLA Integrated Substance Abuse Programs, Los Angeles, CA, United States.
Abstract
BACKGROUND: Opioid dependence is associated with high levels of morbidity, yet sparse data exists regarding the health-related quality of life (HRQoL) of individuals with opioid dependence, particularly following treatment initiation. To inform cost-effectiveness analyses of treatment modalities, this study investigates short-term changes in HRQoL following enrollment into opioid agonist treatment (OAT), across treatment modalities and patient subgroups. METHODS: Data was analyzed from the Starting Treatment with Agonist Replacement Therapies (START) and Prescription Opioid Addiction Treatment Studies (POATS) randomized controlled trials. Participants included individuals dependent on prescription opioids (POs) or heroin, receiving limited-term or time-unlimited treatment. PO- or heroin-users in START received buprenorphine/naloxone (BUP/NX) or methadone (MET) over 24 weeks. PO-users in POATS received psychosocial care and short-term (4-week) taper with BUP/NX, with non-responders offered subsequent extended (12-week) stabilization and taper. HRQoL was assessed using the short-form SF-6D while in and out of OAT, with distinction between MMT and BUP/NX in START. Linear mixed effects regression models were fitted to determine the independent effects of OAT on HRQoL and characterize HRQoL trajectories. RESULTS: Treatment had a similar immediate and modest positive association with HRQoL in each patient subgroup. The association of OAT on HRQoL was statistically significant in each model, with effect sizes between 0.039 (heroin-users receiving BUP/NX) and 0.071 (PO-users receiving MET). After initial improvement, HRQoL decreased slightly, or increased at a diminished rate. CONCLUSIONS: OAT, whether delivered in time-limited or unlimited form, using BUP/NX or MET, is associated with modest immediate HRQoL improvements, with diminishing benefits thereafter.
BACKGROUND:Opioid dependence is associated with high levels of morbidity, yet sparse data exists regarding the health-related quality of life (HRQoL) of individuals with opioid dependence, particularly following treatment initiation. To inform cost-effectiveness analyses of treatment modalities, this study investigates short-term changes in HRQoL following enrollment into opioid agonist treatment (OAT), across treatment modalities and patient subgroups. METHODS: Data was analyzed from the Starting Treatment with Agonist Replacement Therapies (START) and Prescription Opioid Addiction Treatment Studies (POATS) randomized controlled trials. Participants included individuals dependent on prescription opioids (POs) or heroin, receiving limited-term or time-unlimited treatment. PO- or heroin-users in START received buprenorphine/naloxone (BUP/NX) or methadone (MET) over 24 weeks. PO-users in POATS received psychosocial care and short-term (4-week) taper with BUP/NX, with non-responders offered subsequent extended (12-week) stabilization and taper. HRQoL was assessed using the short-form SF-6D while in and out of OAT, with distinction between MMT and BUP/NX in START. Linear mixed effects regression models were fitted to determine the independent effects of OAT on HRQoL and characterize HRQoL trajectories. RESULTS: Treatment had a similar immediate and modest positive association with HRQoL in each patient subgroup. The association of OAT on HRQoL was statistically significant in each model, with effect sizes between 0.039 (heroin-users receiving BUP/NX) and 0.071 (PO-users receiving MET). After initial improvement, HRQoL decreased slightly, or increased at a diminished rate. CONCLUSIONS:OAT, whether delivered in time-limited or unlimited form, using BUP/NX or MET, is associated with modest immediate HRQoL improvements, with diminishing benefits thereafter.
Keywords:
Buprenorphine/naloxone; HRQoL; Health related quality of life; Health utility; Methadone; Opioid agonist treatment; Opioid use disorder; Suboxone
Authors: Eleanor M Pullenayegum; Jean-Eric Tarride; Feng Xie; Ron Goeree; Hertzel C Gerstein; Daria O'Reilly Journal: Value Health Date: 2010-03-10 Impact factor: 5.725
Authors: P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; Jeffrey Hsu; Joshua Boverman; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Jeremy W Bray; Brandon Aden; Ashley A Eggman; Leah Hellerstein; Eve Wittenberg; Bohdan Nosyk; Judy C Stribling; Bruce R Schackman Journal: J Subst Abuse Treat Date: 2017-02-10
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: Ali Jalali; Danielle A Ryan; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492